BR0008135A - Composto, métodos para tratar uma infecção por vìrus em um ser humano e para tratar uma infecção pelo vìrus da hepatite b em um ser humano, composição farmacêutica, uso de um composto, método para liberar um composto, pacote para paciente, processo para a preparação de um composto - Google Patents

Composto, métodos para tratar uma infecção por vìrus em um ser humano e para tratar uma infecção pelo vìrus da hepatite b em um ser humano, composição farmacêutica, uso de um composto, método para liberar um composto, pacote para paciente, processo para a preparação de um composto

Info

Publication number
BR0008135A
BR0008135A BR0008135-3A BR0008135A BR0008135A BR 0008135 A BR0008135 A BR 0008135A BR 0008135 A BR0008135 A BR 0008135A BR 0008135 A BR0008135 A BR 0008135A
Authority
BR
Brazil
Prior art keywords
compound
human
virus infection
treating
hepatitis
Prior art date
Application number
BR0008135-3A
Other languages
English (en)
Inventor
Susan Mary Daluge
Christopher Mcguigan
Original Assignee
Glaxo Group Ltd
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9903090.0A external-priority patent/GB9903090D0/en
Application filed by Glaxo Group Ltd, Univ Cardiff filed Critical Glaxo Group Ltd
Publication of BR0008135A publication Critical patent/BR0008135A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Abstract

"COMPOSTO, MéTODOS PARA TRATAR UMA INFECçãO POR VìRUS EM UM SER HUMANO E PARA TRATAR UMA INFECçãO PELO VìRUS DA HEPATITE B EM UM SER HUMANO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, MéTODO PARA LIBERAR UM COMPOSTO, PACOTE PARA PACIENTE, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". A presente invenção diz respeito a análogos de (1R,cis)-4-(6amino-9H-purin-9-il)-2-ciclopenteno-1-metanol, a processos para a sua preparação e a seu uso no tratamento de infecções virais.
BR0008135-3A 1999-02-12 2000-02-10 Composto, métodos para tratar uma infecção por vìrus em um ser humano e para tratar uma infecção pelo vìrus da hepatite b em um ser humano, composição farmacêutica, uso de um composto, método para liberar um composto, pacote para paciente, processo para a preparação de um composto BR0008135A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9903090.0A GB9903090D0 (en) 1999-02-12 1999-02-12 Therapeutic compounds
US17020599P 1999-12-10 1999-12-10
PCT/EP2000/001045 WO2000047591A1 (en) 1999-02-12 2000-02-10 Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents

Publications (1)

Publication Number Publication Date
BR0008135A true BR0008135A (pt) 2002-02-19

Family

ID=26315118

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008135-3A BR0008135A (pt) 1999-02-12 2000-02-10 Composto, métodos para tratar uma infecção por vìrus em um ser humano e para tratar uma infecção pelo vìrus da hepatite b em um ser humano, composição farmacêutica, uso de um composto, método para liberar um composto, pacote para paciente, processo para a preparação de um composto

Country Status (24)

Country Link
US (1) US7115590B1 (pt)
EP (1) EP1150988B1 (pt)
JP (1) JP2002536452A (pt)
KR (1) KR20010102082A (pt)
CN (1) CN1346360A (pt)
AR (1) AR031975A1 (pt)
AT (1) ATE241633T1 (pt)
AU (1) AU772478B2 (pt)
BR (1) BR0008135A (pt)
CA (1) CA2362662A1 (pt)
CZ (1) CZ20012908A3 (pt)
DE (1) DE60002986T2 (pt)
DK (1) DK1150988T3 (pt)
DZ (1) DZ3007A1 (pt)
ES (1) ES2200820T3 (pt)
HK (1) HK1039337B (pt)
HU (1) HUP0105476A3 (pt)
IL (1) IL144647A0 (pt)
NO (1) NO20013910L (pt)
NZ (1) NZ513450A (pt)
PL (1) PL204458B1 (pt)
PT (1) PT1150988E (pt)
TR (1) TR200102313T2 (pt)
WO (1) WO2000047591A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010915A1 (es) * 1999-12-10 2001-09-29 Glaxo Group Ltd Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales
EP1235834A1 (en) * 1999-12-10 2002-09-04 Glaxo Group Limited (1r,cis)-4-(4-amino-7h-pyrr0l0[2,3- i(d)]pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral
EP1294735A2 (en) 2000-05-26 2003-03-26 Novirio Pharmaceuticals Limited Methods and compositions for treating flaviviruses and pestiviruses
CZ304734B6 (cs) † 2000-07-21 2014-09-10 Gilead Sciences, Inc. Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu
GB0129945D0 (en) * 2001-12-13 2002-02-06 Mrc Technology Ltd Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
EP2768838A1 (en) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
NZ702744A (en) 2012-05-22 2016-12-23 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
UY34824A (es) 2012-05-25 2013-11-29 Janssen R & D Ireland Nucleósidos de espirooxetano de uracilo
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
EA030189B8 (ru) 2012-10-08 2018-10-31 Иденикс Фармасьютикалз Ллс Аналоги 2'-хлоронуклеозидов для инфекции вгс
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
EP2970357A1 (en) 2013-03-13 2016-01-20 IDENIX Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PL3512863T3 (pl) 2016-09-07 2022-04-04 Atea Pharmaceuticals, Inc. 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244896A (en) * 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US6887707B2 (en) * 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
EP1235834A1 (en) * 1999-12-10 2002-09-04 Glaxo Group Limited (1r,cis)-4-(4-amino-7h-pyrr0l0[2,3- i(d)]pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof

Also Published As

Publication number Publication date
EP1150988B1 (en) 2003-05-28
CN1346360A (zh) 2002-04-24
DE60002986T2 (de) 2004-05-19
DE60002986D1 (en) 2003-07-03
AR031975A1 (es) 2003-10-22
HUP0105476A2 (en) 2002-06-29
DK1150988T3 (da) 2003-09-29
ES2200820T3 (es) 2004-03-16
CA2362662A1 (en) 2000-08-17
ATE241633T1 (de) 2003-06-15
HK1039337B (zh) 2003-11-21
WO2000047591A1 (en) 2000-08-17
DZ3007A1 (fr) 2003-03-27
PT1150988E (pt) 2003-10-31
EP1150988A1 (en) 2001-11-07
KR20010102082A (ko) 2001-11-15
NZ513450A (en) 2004-03-26
PL350023A1 (en) 2002-10-21
US7115590B1 (en) 2006-10-03
IL144647A0 (en) 2002-05-23
AU772478B2 (en) 2004-04-29
TR200102313T2 (tr) 2002-03-21
NO20013910L (no) 2001-10-10
CZ20012908A3 (cs) 2002-10-16
NO20013910D0 (no) 2001-08-10
HUP0105476A3 (en) 2002-08-28
PL204458B1 (pl) 2010-01-29
HK1039337A1 (en) 2002-04-19
JP2002536452A (ja) 2002-10-29
AU2671300A (en) 2000-08-29

Similar Documents

Publication Publication Date Title
BR0008135A (pt) Composto, métodos para tratar uma infecção por vìrus em um ser humano e para tratar uma infecção pelo vìrus da hepatite b em um ser humano, composição farmacêutica, uso de um composto, método para liberar um composto, pacote para paciente, processo para a preparação de um composto
DE60105424D1 (de) Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
PT1296711E (pt) E7 de vph para o tratamento do virus do papiloma humano
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
TW246641B (pt)
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
ATE110958T1 (de) Verwendung von sertralin zur behandlung verfrühter ejakulation.
BR9500436A (pt) Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
BR9912142A (pt) 6-benzil-4-oxipirimidinas substituìdas, processopara sua preparação e composições contendo-as
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
ATE122100T1 (de) Humaner monoklonaler antikörper und diesen enthaltende arzneimittelzusammensetzung zur behandlung von pseudomonasinfektionen.
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
KR100227125B1 (ko) 미포자충감염을치료하기위한벤즈이미다졸구충제의용도
ATE295159T1 (de) Bupropion zur behandlung von viralen erkrankungen
UA42693C2 (uk) Лікарський засіб для лікування інфекції лентивірусом, препарат для лікування людини, яка інфікована лентивірусом
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
DK1150981T3 (da) Terapeutisk necleosidforbindelse
UA31649A (uk) Спосіб лікування захворювань, які викликані тоrсн - інфекціями
ATE100318T1 (de) Verwendung von chinolyl- und isochinolyloxazol-2- onen zur herstellung eines arzneimittels zur verhinderung der ansteckungsfaehigkeit von mit glykoproteinen umhuellten viren.
RU94038588A (ru) Способ лечения вторичного иммунодефицита (вид)
BR0207931A (pt) Anticorpos naturais ativos contra vìrus hiv

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.